Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Real-time Estimate Quote. Real-time Estimate CHI-X - 12/01 04:48:14 am
415.075 DKK   -1.10%
04:31aNOVO NORDISK A/S : ESG presentation ()
PU
03:41aNOVO NORDISK : Gets a Buy rating from JP Morgan
MD
11/30Weight-Loss Firm Noom Names First CFO
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

NOVO NORDISK : UBS remains Neutral

08/18/2020 | 05:44am EST

In his latest research note, analyst Michael Leuchten confirms his recommendation. The broker UBS is keeping its Neutral rating. Previously set at DKK 425, the target price has been slightly modified to DKK 415.


© MarketScreener with dpa-AFX Analyser 2020
Stocks mentioned in the article
ChangeLast1st jan.
NOVO NORDISK A/S -1.47% 413.55 Delayed Quote.8.55%
UBS GROUP AG 0.39% 12.925 Delayed Quote.5.44%
All news about NOVO NORDISK A/S
04:31aNOVO NORDISK A/S : ESG presentation ()
PU
03:41aNOVO NORDISK : Gets a Buy rating from JP Morgan
MD
11/30Weight-Loss Firm Noom Names First CFO
DJ
11/23NOVO NORDISK A/S : – Share repurchase programme
AQ
11/20India's Gland Pharma jumps 23% in market debut
RE
11/18NOVO NORDISK A/S : - Once-weekly semaglutide 2.0 mg demonstrates superior reduct..
AQ
11/18NOVO NORDISK A/S : Experts Urge Govt to Subsidise Cost of Diabetes Management, T..
AQ
11/17NOVO NORDISK A/S : Once-weekly semaglutide 2.0 mg demonstrates superior reductio..
AQ
11/16GILEAD SCIENCES : and Novo Nordisk Present New Data from Proof-of-Concept Trial ..
AQ
11/14NOVO NORDISK A/S : Diabetes - Novo Nordisk to Offer Free Insulin to Children in ..
AQ
More news
Financials
Sales 2020 127 B 20 494 M 20 494 M
Net income 2020 42 174 M 6 784 M 6 784 M
Net cash 2020 8 472 M 1 363 M 1 363 M
P/E ratio 2020 23,2x
Yield 2020 2,15%
Capitalization 972 B 156 B 156 B
EV / Sales 2020 7,56x
EV / Sales 2021 7,10x
Nbr of Employees 44 326
Free-Float 75,1%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Average target price 439,69 DKK
Last Close Price 419,70 DKK
Spread / Highest target 29,9%
Spread / Average Target 4,76%
Spread / Lowest Target -30,9%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S8.55%155 951
JOHNSON & JOHNSON-0.82%379 086
ROCHE HOLDING AG-3.66%285 972
PFIZER, INC.3.21%206 939
NOVARTIS AG-11.80%203 829
MERCK & CO., INC.-12.19%202 049